about
Targeting hypoxic response for cancer therapyBroad targeting of angiogenesis for cancer prevention and therapyCrosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironmentIntravascular targets for molecular contrast-enhanced ultrasound imagingNormalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissueTwist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancerEmodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactionsToward a science of tumor forecasting for clinical oncology.Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.Exposure of tumor-associated macrophages to apoptotic MCF-7 cells promotes breast cancer growth and metastasis.Staurosporine Induced Apoptosis May Activate Cancer Stem-Like Cells (CD44(+)/CD24(-)) in MCF-7 by Upregulating Mucin1 and EpCAM.Targeting angiogenesis in metastatic breast cancerBispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancerPhysiological Capillary Regression is not Dependent on Reducing VEGF Expression.Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45AIntracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.Controlling escape from angiogenesis inhibitors.IL-1 drives breast cancer growth and bone metastasis in vivo.Natriuretic peptide receptor A signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis.Sorafenib in locally advanced or metastatic breast cancer.Concomitant resistance and early-breast cancer: should we change treatment strategies?The Herbal Medicine Utrica Dioica Inhibits Proliferation of Colorectal Cancer Cell Line by Inducing Apoptosis and Arrest at the G2/M Phase.Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model.Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells.A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
P2860
Q26767351-8071F7A3-1CA9-404F-B466-8CE504C1FF84Q27002903-97B8DC21-4653-4DF7-82C6-678EF3A8FECFQ28081431-6FAE32EE-8968-42EE-ADE2-AF2EE82FD03EQ30465487-271CF99C-D7B6-496A-9B41-1F0600D56317Q30542073-1C484097-1CB5-4268-8489-65DEFDD5DA3AQ33814571-86B6C483-82CE-4FD8-8EED-485F3D97463CQ33897971-C0EBEF4C-F568-430D-B4BC-FF306EF1A763Q34207659-108D8796-E35C-4928-8A01-F1886CC0F434Q34475456-DF84583B-75C6-46EA-9235-07877B6B7D1AQ34851156-0F774B59-689E-4FB0-90B4-62C1CB679A88Q35023562-A6B83960-1CB5-4D2F-BC77-9AAD8A15C165Q35178358-A1229DE9-2111-4B3F-882C-8A98EF839D82Q35187503-8685AA12-4FCB-427A-98A4-0A59C65788EFQ35742534-6AA1A3A9-218D-4A71-BD8B-038BD5D3D64EQ35813735-1D572703-87D4-447F-A60B-03063BA51EF3Q36048537-976B24C7-CE26-4724-8062-624212DC9F61Q36182795-950DF202-290C-4D87-B033-E1E90AE730A9Q36346628-13468353-1845-4406-A564-38F07C144F69Q36540092-B3D463E4-BD06-4453-8FBA-25CD21613082Q36552345-15AF1E7C-FA89-4186-A2E5-542CCDC8D02AQ36629386-4F9981A5-3FC7-4684-A289-BC2788EA8D00Q36918194-B6744471-C2D5-468F-9471-154F5C3E764FQ37040202-EBA99ACA-FC2A-4192-939A-3E8DF8B22B03Q37411781-7F3CC665-FC76-46CD-8DA7-7E93E62CE046Q37660355-595F4A6C-844E-4526-B265-9EEB17BFF090Q37672654-6B460062-E9EB-4E09-AC7D-793B207E5F63Q37688987-144B19E6-6519-466D-965E-B97C83D52E52Q37695537-1D8F66C5-DFE3-4498-BD32-D82F98AB58FDQ38012156-0AC6BC75-4620-4CE8-85E2-50D71E2DED69Q38171964-055C21D4-B1A8-41AE-9448-F5332784513FQ38777320-480D17CC-5B97-40E4-B320-DED53D4A63C6Q39005705-CBD71C4B-6117-4777-AD60-38E82AA6857CQ42282877-F8F6FA94-0B51-4DE1-8FBB-71E812061B86Q51092841-C520AEEA-162C-487C-959F-EDE1859E1E36Q54349347-E508A12D-DF53-4AD3-8A14-C5766029BAB6
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Reappraising antiangiogenic therapy for breast cancer.
@ast
Reappraising antiangiogenic therapy for breast cancer.
@en
type
label
Reappraising antiangiogenic therapy for breast cancer.
@ast
Reappraising antiangiogenic therapy for breast cancer.
@en
prefLabel
Reappraising antiangiogenic therapy for breast cancer.
@ast
Reappraising antiangiogenic therapy for breast cancer.
@en
P2860
P1433
P1476
Reappraising antiangiogenic therapy for breast cancer.
@en
P2093
Robert S Kerbel
P2860
P304
P356
10.1016/S0960-9776(11)70295-8
P478
20 Suppl 3
P577
2011-10-01T00:00:00Z